Oncoheroes Biosciences

Executive Summary

Oncoheroes Biosciences is a Barcelona-based biotech company dedicated to developing novel small-molecule therapies specifically for pediatric cancers. Unlike many oncology firms that repurpose adult drugs, Oncoheroes focuses on the distinct biology of childhood cancers, aiming to address the urgent unmet need for safer, more effective treatments. Each year, 400,000 children are diagnosed with cancer, and over 70% of survivors suffer from severe long-term side effects due to outdated therapies. The company's mission is to improve survival rates and quality of life for pediatric patients, particularly those with hard-to-treat brain tumors and metastatic sarcomas. Founded in 2016, Oncoheroes operates in the small-molecule space and is privately held. While its pipeline details are not publicly disclosed, the company's targeted approach and experienced team position it as a promising player in the underserved pediatric oncology market. With a strong scientific rationale and a clear patient need, Oncoheroes represents a compelling investment opportunity for those focused on rare disease and child health.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 trial interim data for lead compound in pediatric brain tumors60% success
• Q3 2026Potential Series B financing or non-dilutive grant announcement75% success
• Q2 2026FDA Rare Pediatric Disease Designation for an additional candidate80% success